Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

Breast Cancer Research

Volumn 7, Issue 5, 2005, Pages

  Kucab, Jill E ^a   Lee, Cathy ^a   Chen, Ching Shih ^b   Zhu, Jiuxiang ^b   Gilks, C Blake ^c   Cheang, Maggie ^c   Huntsman, David ^c   Yorida, Erika ^c   Emerman, Joanne ^a   Pollak, Michael ^d   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OHIO STATE UNIVERSITY   (United States)

^c VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; CELECOXIB; CELECOXIB DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE; INITIATION FACTOR 4E BINDING PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OSU 03013; PROTEIN KINASE B; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CELL DEATH; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HER 2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; MDA-MB-453 CELL LINE; NUCLEOSOME; PROTEIN EXPRESSION; SERUM; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; CELL SURVIVAL; FEMALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; FEMALE; HUMANS; MORPHOLINES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 25844469408     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1294     Document Type: Article

References (46)

1. Nielsen T, Andrews H, Cheang M, Kucab JE, Hsu FD, Ragaz J, Gilks CB, Makretsov N, Bajdik CD, Brookes C, et al: Expression of the insulin-like growth factor-1 receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17 allylamino 17-demethoxy geldanamycin. Cancer Res. 2004, 64: 286-291.
2. Sachdev D, Hartwell JS, Lee AV, Zhang X, Yee D: A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem. 2004, 279: 5017-5024 10.1074/jbc.M305403200.
3. Kaleko M, Rutter WG, Miller DA: Overexpression of the human insulin-like growth factor-1 receptor promotes ligand dependent neoplastic transformation. Mol Cell Biol. 1990, 10: 464-473.
4. Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R, Barrett JC: A dominant negative mutant of the insulin-like growth factor-1 receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res. 1998, 58: 3353-3361.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science. 1987, 235: 177-182.
6. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell. 1988, 54: 105-115 10.1016/0092-8674(88)90184-5.
7. Craven RJ, Lightfoot H, Cance WG: A decade of tyrosine kinases: from gene discovery to therapeutics. Surg Oncol. 2003, 12: 39-49 10.1016/S0960-7404(03)00004-5.
8. Cantley LC: The phosphoinositide 3-kinase pathway. Science. 2002, 296: 1655-1657 10.1126/science.296.5573.1655.
9. Scheid MP, Marignani PA, Woodgett JR: Multiple phosphoinosidide 3-kinase dependent steps in activation of protein kinase B. Mol Cell Biol. 2002, 22: 6247-6260 10.1128/MCB.22.17.6247-6260.2002.
10. Cross BAE, Alessi DR, Cohen P, Andjelkovich M, Hemming BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995, 378: 785-789 10.1038/378785a0.
11. Shin I, Yakes FM, Rojo F, Shin NY, Bakin A, Baselga J, Arteaga CL: PKB/AKT mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med. 2002, 8: 1145-1152 10.1038/nm759.
12. Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC: Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by protein kinase B signaling pathway. Proc Nat Acad Sci USA. 1998, 95: 7772-7777 10.1073/pnas.95.13.7772.
13. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: AKT promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell. 1999, 96: 857-868 10.1016/S0092-8674(00)80595-4.
14. Hill MM, Hemmings BA: Inhibition of protein kinase B/Akt: implications for cancer therapy. Pharmacol Ther. 2002, 93: 243-251 10.1016/S0163-7258(02)00193-6.
15. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ: Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated tumorigenesis but suppresses tumor invasion. Cancer Res. 2004, 64: 3171-3178.
16. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, et al: AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol. 2001, 159: 431-437.
17. Clark AS, West K, Streicher S, Dennis PA: Constitutive and inducible Akt activity promotes resistance to chemotherapy, Trastuzumab, or Tamoxifen in breast cancer cells. Mol Cancer Ther. 2002, 1: 707-717.
18. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Lang KK, Milas L, Fan Z: Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther. 2003, 2: 353-360.
19. Luo J, Manning BD, Cantley LC: Targeting the PI3K/Akt pathway in human cancer: Rationale and promise. Cancer Cell. 2003, 4: 257-262 10.1016/S1535-6108(03)00248-4.
20. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med. 2001, 344: 783-792 10.1056/NEJM200103153441101.
21. Cuello M, Ettenberg SA, Clark SS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that express erbB-2. Cancer Res. 2001, 61: 4892-4900.
22. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Faehrenbacher L, Slamon D, Murphy M, Novotny WF, Murchmore M, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of Her-2 overepxressing metastatic breast cancer. J Clin Oncol. 2002, 20: 719-726 10.1200/JCO.20.3.719.
23. Jetzt A, Howe JA, Horn MT, Maxwell E, Yin Z, Johnson D, Kumar CC: Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice. Cancer Res. 2003, 63: 6697-6706.
24. Kozikowski AP, Sun H, Brognard J, Dennis PA: Novel PI analogues selectively block activation of the poor-survival serine/threonine kinase Akt. J Am Chem Soc. 2003, 125: 1144-1145 10.1021/ja0285159.
25. Liu Y, Dan HC, Sun M, Liu Q, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, Sebti SM, et al: Akt/Protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004, 64: 4394-4399.
26. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS: Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor- induced apoptosis in prostate cancer cells. J Natl Cancer Inst. 2002, 94: 585-591.
27. Brune K, Neubert A: Pharmacokinetic and pharmacodynamic aspects of the ideal Cox-2 inhibitor: a pharmacologists perspective. Clin Exp Rheumatol. 2001, 19 (6 Suppl 25): S51-S57.
28. Hsu A, Ching TT, Wang D, Song X, Rangnekar VM, Chen CS: The cyclooxygenase-2 inhibitor Celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of BCL-2. J Biol Chem. 2000, 275: 11397-11403 10.1074/jbc.275.15.11397.
29. Zhu J, Huang J, Tseng PH, Yang Y, Fowble J, Shiau C, Shaw Y, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor Celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase inhibitors. Cancer Res. 2004, 64: 4309-4318.
30. Rapid Access to Preventive Intervention Development (RAPID) program. [ http://www3.cancer.gov/prevention/rapid/ ]
31. Levitt RJ, Pollak M: Insulin-like growth factor-1 antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BXPC-3 pancreatic cancer cells. Cancer Res. 2002, 62: 7372-7376.
32. Oh JS, Buchel P, Martin K, Kucab JE, Oshimura T, Bennett L, Barrett JC, DiAugustine RP, Afshsari C, Dunn SE: Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. Neoplasia. 2002, 4: 204-217 10.1038/sj.neo.7900229.
33. Dunn SE, Hardman R, Kari FW, Barrett JC: Insulin-like growth factor-I alters drug sensitivity of human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997, 57: 2687-2693.
34. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004, 64: 1444-1451.
35. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR, Ellis IO: The role of PTEN and its signaling pathways, including Akt, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004, 204: 93-100 10.1002/path.1611.
36. Sastre-Garau X, Rousseau A, Al Ghuzlan A, Freneaux P, Rosty C, Sigal B-Zafrani, Couturier J, Thiery JP, Magdelenat H, Vincent-Salomon A: Increase cell size and Akt activation in Her-2/neu overexpressing invasive ductal carcinoma of the breast. Histopathology. 2004, 45: 142-147 10.1111/j.1365-2559.2004.01899.x.
37. Schmitz KJ, Otterbach F, Callies R, Levkau B, Holscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA: Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol. 2004, 17: 15-21.
38. Perez-Tenorio G, Stal O: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002, 86: 540-545 10.1038/sj.bjc.6600126.
39. Stal O, Perez-Tenorio G, Akerberg L, Olsson B, Nordenskjold B, Skoog L, Rutqvist LE: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res. 2003, 5: R37-R44 10.1186/bcr569.
40. Arboleda MG, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, Danino M, Karlan BY, Slamon D: Overexpression of Akt2/protein kinase B beta leads to up-regulation of beta1 integrins, increased invasion and metastasis of human breast and ovarian cancer cells. Cancer Res. 2003, 63: 196-206.
41. Ahmad S, Singh N, Glazer RI: Role of AKT1 in 17 b-estradiol and insulin-like growth factor 1 (IGF-1) dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharm. 1999, 58: 425-430 10.1016/S0006-2952(99)00125-2.
42. Tseng PH, Lin HP, Zhu J, Chen K, Hade EM, Young DC, Byrd JC, Grever M, Johnson M, Druker B, et al: Synergistic interactions between Imatinib and the novel phosphoinositide-Dependent kinase-1 inhibitor OSU-03012 in overcoming Imatinib resistance. Blood. 2005.
43. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL: Herceptin-induced inhibition of phosphotidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1 and antitumor action. Cancer Res. 2002, 62: 4132-4141.
44. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietraz R, Slamon D: Rational combinations of trastuzumab with chemotherapeutic drugs in the treatment of breast cancer. J Natl Cancer Inst. 2004, 96: 739-749.
45. Hermanto U, Zong CS, Wang LH: Erb-B2 overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth. Oncogene. 2001, 20: 7551-7562 10.1038/sj.onc.1204964.
46. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidmann AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, et al: Phase II study of Celecoxib and Trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab based treatments. Clin Cancer Res. 2004, 10: 4062-4067.